Voices
Ahmet Dirican: 50% Lower Risk of Recurrence with Atezolizumab in dMMR Colon Cancer
Ahmet Dirican/X

Ahmet Dirican: 50% Lower Risk of Recurrence with Atezolizumab in dMMR Colon Cancer

Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:

“dMMR colon cancer is no longer just a chemotherapy disease.

But what is the right strategy?

ATOMIC (Phase III):

mFOLFOX6 ± atezolizumab

  • DFS benefit.
  • ~50% lower risk of recurrence/death.

But: ~14% still relapse.

So the problem isn’t solved – biology is still resistant.

What comes next?

  • Adjuvant IO (ATOMIC).
  • Neoadjuvant IO (NICHE-2).
  • Or full IO sequencing (AZUR-2).

IO has arrived. Decisions just got harder.”

Ahmet Dirican

Title: Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer

Authors: Frank A. Sinicrope, Fang-Shu Ou, Dirk Arnold, Walter R. Peters, Robert J. Behrens, Christopher H. Lieu, Khalid Matin, Deirdre J. Cohen, Samara L. Potter, Andrew B. Nixon, Lisa A. Kottschade, Emily Kathol, Wendy L. Frankel, Ardaman Shergill, Dennis Hsu, Anke Reinacher-Schick, Paul Mehan, Philip J. Gold, Maged F. Khalil, Tyler Zemla, Clare Gatten, Eileen M. O’Reilly, Jeffrey A. Meyerhardt

Read The Full Article

Ahmet Dirican

Other articles about Colon Cancer on OncoDaily.

 

Ahmet Dirican Andrew B. Nixon Anke Reinacher-Schick Ardaman Shergill cancer Christopher H. Lieu Clare Gatten Colon cancer Deirdre J. Cohen Dennis Hsu Dirk Arnold Eileen M. O'Reilly Emily Kathol Fang-Shu Ou Frank A. Sinicrope Jeffrey A Meyerhardt Khalid Matin Lisa A. Kottschade Maged F. Khalil OncoDaily Oncology Paul Mehan Philip J. Gold Robert J. Behrens Samara L. Potter Tyler Zemla Walter R. Peters Wendy L. Frankel